면책 고지: 이 사이트는 FDA, ClinicalTrials.gov, PubMed, SEC EDGAR 등 공식 공개 데이터를 일반 참고용으로 집계하며, 의학적 조언, 진단, 치료 권고 또는 투자 조언이 아닙니다.

PubMed

Regulating cell and xeno-transplants: Learning from medical device oversight.

PMID: 42722334 ·

A, l, i, , B, , A, b, b, a, s, i, ;, , R, o, b, e, r, t, , M, , C, a, l, i, f, f

학술지American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
연도
PMID42722334

초록

The widespread availability of genetically engineered cellular products and organs for xenotransplantation could address the persistent shortage of human donor organs, but the current regulatory framework, which was originally designed for discrete molecular entities, is poorly suited to the paradigm of innovation in this field. The US Food and Drug Administration requires sponsors to file investigational new drug applications and pursue a Biologics License Application built around a binary, one

공식 출처

PubMed에서 보기 →

데이터는 PubMed / NCBI에서 제공됩니다. 전문과 최신 정보는 반드시 공식 기록을 확인하세요.

↑